VEON FY24 and 4Q24 Trading Update: Strong Delivery in 2024, Digital Services Driving Growth VEON FY24 and 4Q24 Trading Update: Strong Delivery in 2024, Digital Services Driving Growth Dubai, March 20, 2025, 10:10 GST VEON FY24 Highlights Total revenue growth of 8.3% YoY to USD 4,004 million (+14.6% YoY in underlying local currency terms) EBITDA growth of 4.9% YoY to USD 1,691 million (+12.0% YoY in underlying local currency terms) Direct digital revenue growth of 63.0% YoY to USD 460 million (+64.1% YoY in local currency terms), representing 11.5% of revenues for the full year Total...
EQS-News: SAF-HOLLAND SE / Schlagwort(e): Jahresbericht/Personalie SAF-HOLLAND SE: Starke Performance in einem herausfordernden Marktumfeld – bereinigte EBIT-Marge und freier operativer Cashflow auf Rekordniveau 20.03.2025 / 06:59 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Konzernumsatz beläuft sich auf 1.876,7 Mio. Euro (Vorjahr 2.106,2 Mio. Euro) Bereinigte EBIT-Marge mit 10,1 % auf Rekordniveau (Vorjahr 9,6 %) Periodenergebnis trotz deutlichem Umsatzrückgang mit 78,2 Mio. Euro nahezu auf Vorjahresniveau (80,5 Mio. Euro) ...
EQS-News: Nemetschek SE / Schlagwort(e): Jahresergebnis/Prognose Nemetschek Group: Starkes Umsatzwachstum von 17 % bis 19 % bei weiterhin hoher Profitabilität im Geschäftsjahr 2025 erwartet 20.03.2025 / 07:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Corporate News Nemetschek Group: Starkes Umsatzwachstum von 17 % bis 19 % bei weiterhin hoher Profitabilität im Geschäftsjahr 2025 erwartet Erfolgreiches Jahr 2024: Alle Geschäftsziele erreicht oder sogar deutlich übertroffen +16,9 % Umsatzwachstum auf 995,6 Mio. Euro, Umsatzbei...
ALSO Holding AG / Key word(s): AGMEGM ALSO Holding AG: Record dividend approved by AGM 20.03.2025 / 07:00 CET/CEST Emmen, Switzerland, 20 March 2025 PRESS RELEASE ALSO Holding AG: Record dividend approved by AGM +629% since 2011 (from CHF 0.70 to CHF 5.10) The Annual General Meeting on 19 March 2025 approved an increase in the dividend by CHF 0.30 to CHF 5.10. The dividend will be distributed to shareholders starting March 25, 2025. All other proposals of the Board of Directors were also endorsed by a large majority, the 2024 annual report was accepted, and the E...
EQS-News: Schoeller-Bleckmann Oilfield Equipment AG / Schlagwort(e): Jahresergebnis Geschäftsjahr 2024: SBO mit soliden Ergebnissen und hohem Cashflow in schwierigem Marktumfeld 20.03.2025 / 07:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Geschäftsjahr 2024: SBO mit soliden Ergebnissen und hohem Cashflow in schwierigem Marktumfeld Umsatz mit MEUR 560,4 auf hohem Niveau, unterstützt durch Expansion in strategische Märkte EBITDA von MEUR 101,9 (Marge: 18,2%), EBIT liegt bei MEUR 70,1 (Marge: 12,5%) Operativer Cashflow steigt au...
EQS-News: SAF-HOLLAND SE / Key word(s): Annual Report/Personnel SAF-HOLLAND SE: Strong performance in a challenging market environment - adjusted EBIT margin and operating free cash flow at record levels 20.03.2025 / 06:59 CET/CEST The issuer is solely responsible for the content of this announcement. Group sales amounted to EUR 1,876.7 million (previous year: EUR 2,106.2 million) Adjusted EBIT margin at record level of 10.1% (previous year 9.6%) Result for the period of EUR 78.2 million almost at the previous year's level (EUR 80.5 million) despite a significant sales ...
ALSO Holding AG / Schlagwort(e): Generalversammlung ALSO Holding AG: Rekorddividende von GV genehmigt 20.03.2025 / 07:00 CET/CEST Emmen, Schweiz, 20. März 2025 PRESSEMITTEILUNG ALSO Holding AG: Rekorddividende von GV genehmigt +629% seit 2011 (von CHF 0.70 auf CHF 5.10) Die Generalversammlung vom 19. März 2025 hat die Erhöhung der Dividende um 0.30 auf 5.10 CHF genehmigt. Die Dividende wird ab dem 25. März 2025 an die Aktionäre ausgezahlt. Auch alle weiteren Anträge des Verwaltungsrates wurden grossmehrheitlich verabschiedet, der Geschäftsbericht 2024 genehmigt ...
EQS-News: Schoeller-Bleckmann Oilfield Equipment AG / Key word(s): Annual Results Financial year 2024: SBO delivered solid results and high cash flow despite market headwinds 20.03.2025 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Financial year 2024: SBO delivered solid results and high cash flow despite market headwinds Sales at a high level of MEUR 560.4, supported by expansion in strategic markets EBITDA of MEUR 101.9 (margin: 18.2%), EBIT of MEUR 70.1 (margin: 12.5%) Operating cash flow increased to MEUR 98.4, free cash f...
EQS-News: Nemetschek SE / Key word(s): Annual Results/Forecast Nemetschek Group: Strong revenue growth of 17% to 19% with continued high profitability expected in the financial year 2025 20.03.2025 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Corporate News Nemetschek Group: Strong revenue growth of 17% to 19% with continued high profitability expected in the financial year 2025 Successful year 2024: All financial targets achieved or clearly exceeded +16.9% revenue growth to EUR 995.6 million, revenue contribution from GoCanv...
A director at Primoris Services Corp sold/sold after exercising options 61,390 shares at 64.100USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dire...
MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announces that the Company will hold a conference call on Thursday, March 27, 2025 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2024. Participants during the call will be: Jonathan Dickinson, Chief Executive Officer Sonia Quaratino, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Chief Operating Officer Frédéric Lombard, Senior Vice Presi...
IBA reports solid Full Year 2024 results Read the entire full year 2024 results press release Louvain-la-Neuve, Belgium, 20 March 2025 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated results for the 2024 financial year. Record-high revenue and return to profitability in 2024 driven by well-executed backlog conversion Net sales rose 7% to €498.2 million1, with Other Accelerators increasing by 18%Gross margin improvement to 33.3% vs. 28.8% in 2023, driven by higher share of Other Accelerators and margin improv...
IBA publie des résultats solides pour l'année 2024 pour lire l'intégralité du communiqué de presse des résultats de l'exercice 2024 Louvain-La-Neuve, Belgique, jeudi 20 mars 2025 - IBA (Ion Beam Applications S.A.), le leader mondial de la technologie d’accélération de particules, annonce ce jour ses résultats consolidés pour l’exercice 2024. Chiffre d'affaires record et retour à la rentabilité en 2024 grâce à une conversion efficace du carnet de commandes Chiffre d’affaires en hausse de 7% à 498,2 millions d'euros1, dont une augmentation de 18% pour l’activité Autres AccélérateursA...
Arcadis acquires WSP Infrastructure Engineering GmbH, strengthening its position in the attractive German rail market Arcadis acquires WSP Infrastructure Engineering GmbH, strengthening its position in the attractive German rail market Amsterdam, 20 March 2025 – Arcadis, a global leader in intelligence-driven sustainable design, engineering, and consultancy solutions, has announced the acquisition of WSP Infrastructure Engineering GmbH, a 160-people strong, German based engineering firm specialized in rail infrastructure, signaling, structural engineering and software development. This a...
Sodexo First half Fiscal 2025 estimates and full year guidance update Issy-les-Moulineaux, March 20, 2025 (7am)Sodexo (Euronext Paris FR 0000121220-OTC: SDXAY) Sodexo First half Fiscal 2025 estimates and full year guidance update First half Organic revenue growth of +3.5%First half Underlying operating profit up +6.4% at constant currencies, margin up +10bpsUpdate to full year guidance mainly triggered by slower than expected organic growth in North America : Organic revenue growth between +3% and +4% (from between +5.5% and +6.5%)Underlying operating profit margin improvement between +10...
Sodexo : estimation des résultats du 1er semestre et actualisation des perspectives financières pour l'exercice 2025 Issy-les-Moulineaux, le 20 mars 2025 (7h00)Sodexo (Euronext Paris FR 0000121220-OTC: SDXAY) Sodexo : estimation des résultats du 1er semestre et actualisation des perspectives financières pour l'exercice 2025 Croissance interne du chiffre d'affaires pour le 1er semestre de +3,5% Résultat d'exploitation du 1er semestre en hausse de +6,4% à taux constants, marge d'exploitation en hausse de +10 points de baseActualisation des perspectives financières pour l'exercice 2025, prin...
Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to reset the immune systemAcquisition underpins path for Sanofi becoming leading immunology companySanofi to pay $600 million up front Paris, March 20, 2025. Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under ...
Communiqué de presse : Sanofi va acquérir l’anticorps bispécifique de Dren Bio – un « engageur » des cellules myéloïdes pour la déplétion profonde des lymphocytes B –, et étoffe son portefeuille en immunologie Sanofi va acquérir l’anticorps bispécifique de Dren Bio – un « engageur » des cellules myéloïdes pour la déplétion profonde des lymphocytes B –, et étoffe son portefeuille en immunologie L’agent de déplétion profonde des lymphocytes B de Dren Bio peut potentiellement reprogrammer le système immunitaire. Cette acquisition donne à Sanofi un atout supplémentaire pour asseoir son leader...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.